DermaPure to be Showcased in Nine Posters at SAWC

RNS Number : 8682N

Tissue Regenix Group PLC

03 February 2016

 

Tissue Regenix Group plc

("Tissue Regenix or "The Group")

DermaPure® selected to feature nine poster presentations at Woundcare Symposium

York, 03 February 2016 - Tissue Regenix Group plc (AIM:TRX)  ("Tissue Regenix") or ("The Group") the regenerative medical devices company, is pleased to announce Tissue Regenix Wound Care, Inc. will display nine poster presentations at the Symposium on Advanced Wound Care (SAWC) Spring conference to be held in Atlanta, Georgia, April 13-17. 

Focussed on the Groups first commercialised product DermaPure, the posters have been written by various key opinion leaders including Clinicians, Clinical Affairs and researchers. They were selected and approved by a peer review committee and will focus on areas such as; clinical efficacy in various types of wounds, pain reduction, a retrospective analysis of clinical outcomes and an analysis of DermaPure's Extracellular Matrix. 

DermaPure was released to the US market in 2014, and has been used to treat wounds from diabetic or pressure ulcers through to Frostbite. The Medicare 'Q' code became effective January 2015 allowing clinics to be reimbursed for the product and is now available to c.65% of Medicare beneficiaries. Tissue Regenix announced in January 2016 that sales of DermaPure had surpassed $1m since launch.

Greg Bila, President Tissue Regenix Wound Care, Inc.  commented "We are extremely proud of how DermaPure has performed within a competitive marketplace since it was launched in 2014. Having nine posters chosen by a peer review committee to appear at SAWC, I think, illustrates a deeper understanding and appreciation of the dCELL® technology platform, and the difference that a product like DermaPure can make to patient treatment and recovery.  We look forward to discussing   this further at this year's spring SAWC, and I would like to extend my thanks to all who have contributed to these presentations"

Poster titles

Author(s)	Title
Constantine Demou DPM, Brendan McCarty DPM Jennifer Michael DPM	Use of Regenerative, Decellularized Skin Replacement*on Severe Acute Diabetic Foot Wounds Involving Exposed Bone and Tendon: A Three Case Series
Valarie Muehlenbruch, RN, Kate Biasiolli, RN, Patti Gary, RN, CWCN	The Use of a Regenerative, Decellularized Skin Replacement* to Close Partial Foot Amputation Wounds and Contribute to Diabetic Limb Salvage
Jake Lambert, MD	The Effect of Pain in Patients Treated with Decellularized Human Dermal Grafts
Howard Kimmel DPM, Arthur Tallis DPM	The Use of a Decellularized Dermal Allograft in the Treatment of Chronic Venous Leg Ulcers
HowardKimmel DPM	Retrospective Analysis of Utilizing A Decellularized Dermal Allograft to Treat Chronic Wounds
Anna LeMoine, BSc, MSC, PhD; Vassilis Vayianos, BSc, MSc, PhD and Patti Gary, RN, CWCN	Maintenance of Key Extracellular Matrix Components in a Decellularised Human Dermis Product*
Jaminelli Banks, DPM, Robert Frykberg, DPM	Decellularized Human Dermis* Drives Rapid Surface Area Reduction and Closure for Neuropathic Ulcer
Michael Desvigne, MD	Unique Combined Application of an Ovine Collagen Dressing with an Intact Extracellular Matrix (CECM) with a Decellularized Dermis to Assist in Closure of a Radiated Lower Extremity Wound
Michael Desvigne, MD	Optimizing Wound Bed for Application of Cellular Tissue Based Products Using an Ovine Collagen Dressing with an Intact Extracellular Matrix

For more information:

Tissue Regenix Group plc Caitlin Pearson - Corporate Communications Officer	Tel: [phone]
Jefferies International Ltd Simon Hardy / Harry Nicholas	Tel:  [phone]
Tulchan Communications James Macey-White / Matt Low	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

 In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

NRAEAPAAEDPKEFF